New scan lights up hidden gut tumors
NCT ID NCT06091748
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 3 trial tested a special PET-CT scan using a radioactive tracer called gallium-68 DOTATOC to find neuroendocrine tumors in the stomach, intestines, and pancreas. 69 adults with confirmed or suspected tumors received the scan. The goal was to see how accurately the scan could detect these tumors. Results show the scan is a promising tool for diagnosis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gallium-68 DOTATOC (a radioactive tracer for PET-CT imaging)
What this could lead to
If successful, this imaging method could become a standard way to detect and confirm neuroendocrine tumors in the digestive system, helping guide treatment decisions.
What could go wrong
This is a small, single-arm study with 69 participants, so results may not apply to all patients. The scan involves radiation exposure, though at low levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China